Diabetes Remission After LRYGBP With and Without Fundus Resection: a Randomized Clinical Trial

Obes Surg. 2023 Nov;33(11):3373-3382. doi: 10.1007/s11695-023-06857-z. Epub 2023 Oct 2.

Abstract

Background: Glycemic control, after metabolic surgery, is achieved in two stages, initially with neuroendocrine alterations and in the long-term with sustainable weight loss. The resection of the gastric fundus, as the major site of ghrelin production, is probably related with optimized glucose regulation. The aim of the present study is to investigate whether the modification of laparoscopic Roux-en-Y gastric bypass (LRYGBP) with fundus resection offers superior glycemic control, compared to typical LRYGBP.

Materials and methods: Participants were 24 patients with body mass index (BMI) ≥40kg/m2 and type II diabetes mellitus (T2DM), who were randomly assigned to undergo LRYGBP and LRYGBP with fundus resection (LRYGBP+FR). Gastrointestinal (GI) hormones [ghrelin, glucagon-like-peptide-1 (GLP-1), peptide-YY (PYY)] and glycemic parameters (glucose, insulin, HbA1c, C-peptide, insulinogenic index, HOMA-IR) were measured preoperatively, at 6 and 12 months during an oral glucose tolerance test (OGTT).

Results: Ninety-five percent of patients showed complete remission of T2DM after 12 months. LRYGBP+FR was not related with improved glycemic control, compared to LRYGBP. Ghrelin levels were not significantly reduced at 6 and 12 months after LRYGBP+FR. GLP-1 and PYY levels were remarkably increased postprandially in both groups at 6 and 12 months postoperatively (p<0.01). Patients who underwent LRYGBP+FR achieved a significantly lower BMI at 12 months in comparison to LRYGBP (p<0.05).

Conclusion: Fundus resection is not associated with improved glycemic regulation, compared to typical LRYGBP and the significant decrease in BMI after LRYGBP+FR has to be further confirmed with longer follow-up.

Keywords: Bariatric surgery; Diabetes mellitus type 2; Gastric fundus; Gastrointestinal hormones; Ghrelin.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Diabetes Mellitus, Type 2* / surgery
  • Gastric Bypass*
  • Gastrointestinal Hormones* / metabolism
  • Ghrelin
  • Glucagon-Like Peptide 1 / metabolism
  • Glucose
  • Humans
  • Laparoscopy*
  • Obesity, Morbid* / surgery
  • Peptide YY / metabolism

Substances

  • Ghrelin
  • Gastrointestinal Hormones
  • Glucagon-Like Peptide 1
  • Peptide YY
  • Glucose